Physician profile

Kevin Cullen

Hospitalist · Harlingen, TX

NPI 1679769723

$256.14

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$107.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $65.93 2022-2024
Merck Sharp & Dohme LLC $30.38 2020-2023 Dificid, Zerbaxa
Daiichi Sankyo INC. $28.86 2019-2020
Astrazeneca Pharmaceuticals LP $24.40 2020
E.R. Squibb & Sons, L.L.C. $23.44 2023 Eliquis
Boston Scientific Corporation $19.60 2020
Astellas Pharma US INC $19.32 2019
Abbott Laboratories $18.77 2023 Jot Dx
Allergan, INC. $13.08 2020
Janssen Pharmaceuticals, INC $12.36 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kevin Cullen

$256.14

in general payments reported 2019-2025

Years
2019-2024
Top company
Pfizer INC.

https://glasscript.com/doctor/980665/kevin-cullen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.